Suhas Tambe

Bengaluru, KA 560058, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

A new potent and selective peroxisome proliferator-activated receptor alpha partial agonist displays anti-steatotic effects In vitro and behaves as a safe hypolipidemic and hypoglycemic agent in a diabetic mouse model.

A new potent and selective peroxisome proliferator-activated receptor alpha partial agonist displays anti-steatotic effects In vitro and behaves as a safe hypolipidemic and hypoglycemic agent in a diabetic mouse model.

Journal: European journal of medicinal chemistry

Published: February 26, 2025

Corrigendum to "A chemical modification of a peroxisome proliferator-activated receptor pan agonist produced a shift to a new dual alpha/gamma partial agonist endowed with mitochondrial pyruvate carrier inhibition and antidiabetic properties" [Eur. J. Med. Chem. 275 (2024) 116567].

Corrigendum to "A chemical modification of a peroxisome proliferator-activated receptor pan agonist produced a shift to a new dual alpha/gamma partial agonist endowed with mitochondrial pyruvate carrier inhibition and antidiabetic properties" [Eur. J. Med. Chem. 275 (2024) 116567].

Journal: European journal of medicinal chemistry

Published: February 13, 2025

A chemical modification of a peroxisome proliferator-activated receptor pan agonist produced a shift to a new dual alpha/gamma partial agonist endowed with mitochondrial pyruvate carrier inhibition and antidiabetic properties.

A chemical modification of a peroxisome proliferator-activated receptor pan agonist produced a shift to a new dual alpha/gamma partial agonist endowed with mitochondrial pyruvate carrier inhibition and antidiabetic properties.

Journal: European journal of medicinal chemistry

Published: April 12, 2024

A New Antidiabetic Agent Showing Short- and Long-Term Effects Due to Peroxisome Proliferator-Activated Receptor Alpha/Gamma Dual Agonism and Mitochondrial Pyruvate Carrier Inhibition.

A New Antidiabetic Agent Showing Short- and Long-Term Effects Due to Peroxisome Proliferator-Activated Receptor Alpha/Gamma Dual Agonism and Mitochondrial Pyruvate Carrier Inhibition.

Journal: Journal of medicinal chemistry

Published: February 15, 2023

Effect of parthenolide, an NLRP3 inflammasome inhibitor, on insulin resistance in high-fat diet-obese mice.

Effect of parthenolide, an NLRP3 inflammasome inhibitor, on insulin resistance in high-fat diet-obese mice.

Journal: Canadian journal of physiology and pharmacology

Published: February 04, 2022

Design and synthesis of novel spirocyclic carboxylic acids as potent and orally bioavailable DGAT1 inhibitors and their biological evaluation.

Design and synthesis of novel spirocyclic carboxylic acids as potent and orally bioavailable DGAT1 inhibitors and their biological evaluation.

Journal: Bioorganic & medicinal chemistry letters

Published: December 08, 2021

Recombinant irisin induces weight loss in high fat DIO mice through increase in energy consumption and thermogenesis.

Recombinant irisin induces weight loss in high fat DIO mice through increase in energy consumption and thermogenesis.

Journal: Biochemical and biophysical research communications

Published: August 13, 2019

Discovery of liver-directed glucokinase activator having anti-hyperglycemic effect without hypoglycemia.

Discovery of liver-directed glucokinase activator having anti-hyperglycemic effect without hypoglycemia.

Journal: European journal of medicinal chemistry

Published: December 26, 2016

Showing 1-8 of 8

Last Updated: 09/26/2026